[go: up one dir, main page]

GT201300238A - Imidazopiridazinas como inhibidores de quinasa akt - Google Patents

Imidazopiridazinas como inhibidores de quinasa akt

Info

Publication number
GT201300238A
GT201300238A GT201300238A GT201300238A GT201300238A GT 201300238 A GT201300238 A GT 201300238A GT 201300238 A GT201300238 A GT 201300238A GT 201300238 A GT201300238 A GT 201300238A GT 201300238 A GT201300238 A GT 201300238A
Authority
GT
Guatemala
Prior art keywords
imidazopiridazinas
quinasa
akt inhibitors
neoplasia
akt
Prior art date
Application number
GT201300238A
Other languages
English (en)
Inventor
Bärfacker Lars
Scott William Johnston
Hägebarth Andrea
Ince Stuart
Rehwinkel Hartmut
Politz Oliver
Neuhaus Roland
Briem Hans
Bömer Ulf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201300238A publication Critical patent/GT201300238A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

COMPUESTO DERIVADO DE IMIDAZOPIRIDAZINAS Y COMPUESTOS A PARTIR D DICHA FORMA, PARA EL TRATAMIENTO DE NEOPLASIA BENIGNA O NEOPLASIA MALIGNA, INCLUYENDO CÁNCER DE MAMAS.
GT201300238A 2011-04-07 2013-10-07 Imidazopiridazinas como inhibidores de quinasa akt GT201300238A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07

Publications (1)

Publication Number Publication Date
GT201300238A true GT201300238A (es) 2015-04-06

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300238A GT201300238A (es) 2011-04-07 2013-10-07 Imidazopiridazinas como inhibidores de quinasa akt

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
LT2303021T (lt) 2008-06-16 2019-06-25 University Of Tennessee Research Foundation Junginiai, skirti vėžio gydymui
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
SI2694510T1 (sl) * 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
JP6106694B2 (ja) * 2012-01-10 2017-04-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Aktキナーゼ阻害剤としての置換ピラゾロピリミジン類
SG11201503688SA (en) * 2012-11-30 2015-06-29 Glaxosmithkline Llc Novel pharmaceutical composition
CN109568312A (zh) 2013-03-05 2019-04-05 田纳西大学研究基金会 用于治疗癌症的化合物
US20150352121A1 (en) * 2013-03-12 2015-12-10 Glaxosmithkline Llc Combination
WO2014153001A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Combination therapy for treating cancer
CN105899512A (zh) * 2014-01-09 2016-08-24 拜耳医药股份公司 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
US10774086B2 (en) 2016-11-28 2020-09-15 Bristol-Myers Squibb Company GSK-3 inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
CN1308327C (zh) 2000-04-27 2007-04-04 安斯泰来制药有限公司 咪唑并吡啶衍生物
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN1809354A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
BRPI0412636A (pt) 2003-07-30 2006-09-26 S A L V A T Lab Sa imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
US7655649B2 (en) 2004-04-09 2010-02-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
KR20070054216A (ko) 2004-08-24 2007-05-28 바스프 악티엔게젤샤프트 이온성 액체 제조의 출발 화합물로서의 용도를 위한이미다졸륨-메틸술파이트
WO2006065601A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
MX2007014510A (es) 2005-05-20 2008-02-05 Array Biopharma Inc Compuestos inhibidores de raf y metodos de uso de los mismos.
HRP20130429T1 (en) 2005-06-10 2013-06-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
SG182187A1 (en) * 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
PE20090944A1 (es) 2007-08-14 2009-08-09 Bayer Schering Pharma Ag PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
AU2008288390A1 (en) * 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
EP2235019A1 (en) 2007-12-21 2010-10-06 Wyeth LLC Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8207169B2 (en) 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CA2750051A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MX2011008583A (es) * 2009-02-13 2011-12-12 Bayer Pharma AG Pirimidinas fusionadas.
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2413932A4 (en) * 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011033265A1 (en) * 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds
JP5830094B2 (ja) * 2010-07-12 2015-12-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾ[1,2−a]ピリミジンおよび−ピリジン
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
SI2694510T1 (sl) * 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze

Also Published As

Publication number Publication date
HRP20160011T1 (hr) 2016-02-12
SG193631A1 (en) 2013-11-29
DK2694510T3 (en) 2016-01-18
WO2012136776A1 (en) 2012-10-11
BR112013025777A2 (pt) 2016-12-20
TN2013000400A1 (en) 2015-03-30
NZ616270A (en) 2015-09-25
ES2558780T3 (es) 2016-02-08
KR20140022057A (ko) 2014-02-21
US20140113901A1 (en) 2014-04-24
PL2694510T3 (pl) 2016-03-31
JO3068B1 (ar) 2017-03-15
CN103596957B (zh) 2016-12-07
RS54480B1 (sr) 2016-06-30
JP5906303B2 (ja) 2016-04-20
AU2012238589B2 (en) 2017-02-16
SMT201600001B (it) 2016-02-25
EA024890B1 (ru) 2016-10-31
DOP2013000226A (es) 2013-11-15
CU24263B1 (es) 2017-07-04
MX2013011699A (es) 2014-01-31
MA35016B1 (fr) 2014-04-03
ZA201307223B (en) 2014-12-23
US9206185B2 (en) 2015-12-08
EP2694510A1 (en) 2014-02-12
SI2694510T1 (sl) 2016-02-29
PE20141380A1 (es) 2014-10-18
ECSP13013008A (es) 2013-12-31
AR087148A1 (es) 2014-02-26
UA111739C2 (uk) 2016-06-10
PT2694510E (pt) 2016-02-08
MX336865B (es) 2016-02-04
US9604989B2 (en) 2017-03-28
NI201300105A (es) 2014-07-14
HUE026323T2 (en) 2016-05-30
EP2694510B1 (en) 2015-10-14
UY34006A (es) 2012-10-31
IL228567A0 (en) 2013-12-31
AP2013007215A0 (en) 2013-10-31
TW201245204A (en) 2012-11-16
CL2013002878A1 (es) 2014-05-02
US20150368250A1 (en) 2015-12-24
CY1117163T1 (el) 2017-04-05
ME02316B (me) 2016-06-20
PH12013502073A1 (en) 2014-01-13
TWI535719B (zh) 2016-06-01
JP2014510127A (ja) 2014-04-24
CA2832374A1 (en) 2012-10-11
AP3597A (en) 2016-02-19
CN103596957A (zh) 2014-02-19
CU20130135A7 (es) 2014-02-28
CR20130515A (es) 2013-12-04
AU2012238589A1 (en) 2013-11-07
EA201301130A1 (ru) 2014-07-30
CO6862145A2 (es) 2014-02-10

Similar Documents

Publication Publication Date Title
GT201300238A (es) Imidazopiridazinas como inhibidores de quinasa akt
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
EA201400178A1 (ru) Лечение рака молочной железы
CL2016001733A1 (es) Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12.
MX2015002040A (es) Baricitinib deuterado.
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
LT3447061T (lt) Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
UY34145A (es) Compuestos inhibidores de metaloenzimas
IN2015DN00598A (es)
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
DOP2015000060A (es) Profármacos de aminoquinazolina inhibidora de cinasa
BR112013024211A2 (pt) tratamento de tumores sólidos
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IL244884B (en) Antibodies conjugated against ly75 for cancer therapy
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
MX2015008829A (es) Momelotinib deuterado.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015012610A (es) Pacritinib deuterizado.
UA88965U (uk) Сполука 1,3-біс-(2-гидроксіетил)-урацил, що має інотропну активність
UA54529U (ru) Способ лечения больных раком
UA87254U (ru) Соединение 1,1-диэтилкарбокси-2-метокси-2-трифторметилэтилен с потенциальными физиологическими свойствами
UA89447U (ru) Соединение 1,1-диэтилкарбокси-2-хлор-2-трифторметилэтилен с потенциальными физиологическими свойствами